NICE rules out RA drug abatacept

The rheumatoid arthritis (RA) drug abatacept is too expensive to be prescribed on the NHS, according to NICE.

In a draft single technology appraisal of the drug, released last week, NICE said abatacept was as effective as the other cytokine inhibitor rituximab for RA, but cost twice as much.

Rituximab was recently approved for use with methotrexate in RA patients who failed to respond to other disease-modifying anti-rheumatic drugs (DMARDs).

A NICE spokesman said: 'While recognising the severity of RA, it was concluded that based on this evidence, abatacept could not be considered good use of NHS resources.'

Chief executive of the National Rheumatoid Arthritis Society Ailsa Bosworth said: 'To deny patients abatacept is to deny people with an aggressive and severe form of RA a chance of controlling the disease.'

Last week NICE issued final guidance on the use of tumour necrosis factor alpha blockers for RA. Adalimumab, etanercept and infliximab are recommended in patients with confirmed active RA who have already been trialled with at least two other DMARDs, including methotrexate.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP personally calling at-risk patients to boost COVID-19 vaccine uptake

London GP Dr Farzana Hussain is personally telephoning scores of patients who have...

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Half of patients with possible cancer symptoms avoided contacting GP in first wave

Almost half of people who experienced potential cancer symptoms in the first wave...

GP premises need major investment to let PCNs recruit, warns BMA

GP premises need major investment to let PCNs recruit, warns BMA

Primary care networks (PCNs) are struggling to make use of hundreds of millions of...

NHS unveils £4.2m fund to tackle vaccine inequality

NHS unveils £4.2m fund to tackle vaccine inequality

CCGs with low uptake of COVID-19 vaccine in ethnic minority, marginalised or deprived...

150,000 more people with learning disabilities prioritised for COVID-19 vaccine

150,000 more people with learning disabilities prioritised for COVID-19 vaccine

Around 150,000 more people will be prioritised for COVID-19 vaccination after the...